HER2 Clinical Trials

402 recruitingLast updated: July 17, 2026

There are 402 actively recruiting her2 clinical trials across 64 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4, Early Phase 1. Top locations include Houston, Texas, United States, Boston, Massachusetts, United States, Nashville, Tennessee, United States. Updated daily from ClinicalTrials.gov.


HER2 Trials at a Glance

402 actively recruiting trials for her2 are listed on ClinicalTrialsFinder across 6 cities in 64 countries. The largest study group is Phase 2 with 203 trials, with the heaviest enrollment activity in Houston, Boston, and Nashville. Lead sponsors running her2 studies include Fudan University, Henan Cancer Hospital, and Novartis Pharmaceuticals.

Treatments under study

About HER2 Clinical Trials

Looking for clinical trials for HER2? There are currently 10 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new HER2 trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about HER2 clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 402 trials

Recruiting
Phase 2

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

HER2-negative Breast CancerHormone Receptor-Positive Breast CancerLocoregional Recurrence
Oana Danciu200 enrolled21 locationsNCT05467891
Recruiting
Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Malignant Female Reproductive System Neoplasm+12 more
National Cancer Institute (NCI)2,900 enrolled481 locationsNCT05564377
Recruiting
Phase 1Phase 2

Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors

Melanoma (Skin Cancer)HER2-low Hormone Receptor Positive Breast Cancer
Aminex Therapeutics, Inc.92 enrolled17 locationsNCT07287917
Recruiting
Phase 3

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

Estrogen Receptor-Positive Breast CarcinomaHER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8+2 more
National Cancer Institute (NCI)1,978 enrolled61 locationsNCT07391774
Recruiting
Phase 2

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Breast CancerHER2-positive Breast Cancer
Jazz Pharmaceuticals125 enrolled33 locationsNCT07102381
Recruiting
Phase 1Phase 2

Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

HER2-Positive Solid Tumor
Yuhan Corporation147 enrolled19 locationsNCT05523947
Recruiting
Phase 2

SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment

HER2-positive, Unresectable, Locally Advanced or Metastatic Breast CancerSKB264Inetetamab
Fudan University48 enrolled1 locationNCT07182721
Recruiting
Not Applicable

Evaluating the Effectiveness of Typology-based Coaching on Patients' Therapy Management

HR+/HER2- Early Breast Cancer
Institut fuer Frauengesundheit548 enrolled3 locationsNCT07708571
Recruiting

Pre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast Cancer

Breast NeoplasmsHR+/HER2- Breast Cancer
Fujian Cancer Hospital100 enrolled5 locationsNCT07702708
Recruiting
Phase 1Phase 2

Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure

Breast CancerMetastatic Breast CancerHER2-positive Breast Cancer+1 more
Tianjin Medical University Cancer Institute and Hospital94 enrolled1 locationNCT07708194
Recruiting
Phase 2

Neoadjuvant High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy for ER-Positive /HER2-Negative Breast Cancer

ER+/HER2- Breast Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University30 enrolled1 locationNCT06964906
Recruiting
Phase 1

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+13 more
National Cancer Institute (NCI)36 enrolled2 locationsNCT07137416
Recruiting
Phase 3

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

HER2-Negative Breast CarcinomaAnatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8+1 more
National Cancer Institute (NCI)3,680 enrolled543 locationsNCT06058377
Recruiting
Phase 2

ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer

HER2-negative Breast CancerBreast Cancer Early Stage Breast Cancer (Stage 1-3)Hormone Receptor-Positive Breast Cancer+3 more
Peking University People's Hospital393 enrolled1 locationNCT06970912
Recruiting
Phase 2

CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment

HER2-negative Breast CancerHormone Receptor-Positive Breast CancerEarly Stage Breast Cancer+2 more
Peking University People's Hospital158 enrolled1 locationNCT07366112
Recruiting
Phase 4

Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer

Advanced Breast CancerHER2 + Breast Cancer
Peking University People's Hospital500 enrolled1 locationNCT07600164
Recruiting
Phase 1Phase 2

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors

Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsExtensive-stage Small-cell Lung Cancer
Novartis Pharmaceuticals280 enrolled33 locationsNCT06726148
Recruiting
Phase 2

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas

Esophageal AdenocarcinomaGastric AdenocarcinomaHER2-negative+1 more
Gilead Sciences120 enrolled4 locationsNCT07546812
Recruiting
Phase 3

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Merck Sharp & Dohme LLC2,400 enrolled314 locationsNCT06966700
Recruiting
Phase 3

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

ER-positive, HER2-negative Breast Cancer
AstraZeneca150 enrolled84 locationsNCT07647328